vs

Side-by-side financial comparison of CENTRUS ENERGY CORP (LEU) and Tarsus Pharmaceuticals, Inc. (TARS). Click either name above to swap in a different company.

Tarsus Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($151.7M vs $146.2M, roughly 1.0× CENTRUS ENERGY CORP). On growth, Tarsus Pharmaceuticals, Inc. posted the faster year-over-year revenue change (128.4% vs -3.6%). Tarsus Pharmaceuticals, Inc. produced more free cash flow last quarter ($13.0M vs $-58.0M). Over the past eight quarters, Tarsus Pharmaceuticals, Inc.'s revenue compounded faster (134.4% CAGR vs 82.9%).

Centrus Energy Corp. is an American company that supplies nuclear fuel for use in nuclear power plants and works to develop and deploy centrifuge technology to produce enriched uranium for commercial and government uses, including for national security.

Tarsus Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative therapeutic candidates for unmet medical needs in ophthalmology, dermatology, and other specialty care areas. It operates primarily in the United States, with lead product candidates targeting common, underdiagnosed conditions including demodex blepharitis and rosacea.

LEU vs TARS — Head-to-Head

Bigger by revenue
TARS
TARS
1.0× larger
TARS
$151.7M
$146.2M
LEU
Growing faster (revenue YoY)
TARS
TARS
+132.0% gap
TARS
128.4%
-3.6%
LEU
More free cash flow
TARS
TARS
$71.0M more FCF
TARS
$13.0M
$-58.0M
LEU
Faster 2-yr revenue CAGR
TARS
TARS
Annualised
TARS
134.4%
82.9%
LEU

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
LEU
LEU
TARS
TARS
Revenue
$146.2M
$151.7M
Net Profit
$-8.4M
Gross Margin
23.9%
Operating Margin
8.8%
-5.3%
Net Margin
-5.5%
Revenue YoY
-3.6%
128.4%
Net Profit YoY
63.8%
EPS (diluted)
$0.52
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LEU
LEU
TARS
TARS
Q4 25
$146.2M
$151.7M
Q3 25
$74.9M
$118.7M
Q2 25
$154.5M
$102.7M
Q1 25
$73.1M
$78.3M
Q4 24
$151.6M
$66.4M
Q3 24
$57.7M
$48.1M
Q2 24
$189.0M
$40.8M
Q1 24
$43.7M
$27.6M
Net Profit
LEU
LEU
TARS
TARS
Q4 25
$-8.4M
Q3 25
$3.9M
$-12.6M
Q2 25
$28.9M
$-20.3M
Q1 25
$27.2M
$-25.1M
Q4 24
$-23.1M
Q3 24
$-5.0M
$-23.4M
Q2 24
$30.6M
$-33.3M
Q1 24
$-6.1M
$-35.7M
Gross Margin
LEU
LEU
TARS
TARS
Q4 25
23.9%
Q3 25
-5.7%
Q2 25
34.9%
Q1 25
45.0%
Q4 24
40.8%
Q3 24
15.4%
Q2 24
19.3%
Q1 24
9.8%
Operating Margin
LEU
LEU
TARS
TARS
Q4 25
8.8%
-5.3%
Q3 25
-22.2%
-12.2%
Q2 25
21.7%
-21.6%
Q1 25
28.0%
-33.5%
Q4 24
29.7%
-36.8%
Q3 24
-13.2%
-52.3%
Q2 24
11.2%
-81.6%
Q1 24
-24.3%
-136.5%
Net Margin
LEU
LEU
TARS
TARS
Q4 25
-5.5%
Q3 25
5.2%
-10.6%
Q2 25
18.7%
-19.8%
Q1 25
37.2%
-32.1%
Q4 24
-34.8%
Q3 24
-8.7%
-48.7%
Q2 24
16.2%
-81.6%
Q1 24
-14.0%
-129.4%
EPS (diluted)
LEU
LEU
TARS
TARS
Q4 25
$0.52
$-0.17
Q3 25
$0.19
$-0.30
Q2 25
$1.59
$-0.48
Q1 25
$1.60
$-0.64
Q4 24
$3.26
$-0.57
Q3 24
$-0.30
$-0.61
Q2 24
$1.89
$-0.88
Q1 24
$-0.38
$-1.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LEU
LEU
TARS
TARS
Cash + ST InvestmentsLiquidity on hand
$2.0B
$417.3M
Total DebtLower is stronger
$1.2B
$72.4M
Stockholders' EquityBook value
$765.1M
$343.4M
Total Assets
$2.4B
$562.2M
Debt / EquityLower = less leverage
1.54×
0.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LEU
LEU
TARS
TARS
Q4 25
$2.0B
$417.3M
Q3 25
$1.6B
$401.8M
Q2 25
$833.0M
$381.1M
Q1 25
$653.0M
$407.9M
Q4 24
$671.4M
$291.4M
Q3 24
$194.3M
$317.0M
Q2 24
$227.0M
$323.6M
Q1 24
$209.3M
$298.5M
Total Debt
LEU
LEU
TARS
TARS
Q4 25
$1.2B
$72.4M
Q3 25
$1.2B
$72.3M
Q2 25
$390.0M
$72.1M
Q1 25
$389.5M
$72.0M
Q4 24
$472.5M
$71.8M
Q3 24
$83.5M
$71.7M
Q2 24
$86.5M
$71.6M
Q1 24
$86.5M
$29.9M
Stockholders' Equity
LEU
LEU
TARS
TARS
Q4 25
$765.1M
$343.4M
Q3 25
$363.1M
$335.1M
Q2 25
$359.1M
$332.6M
Q1 25
$213.9M
$342.5M
Q4 24
$161.4M
$224.5M
Q3 24
$76.4M
$237.5M
Q2 24
$76.6M
$252.2M
Q1 24
$33.8M
$275.2M
Total Assets
LEU
LEU
TARS
TARS
Q4 25
$2.4B
$562.2M
Q3 25
$2.2B
$534.6M
Q2 25
$1.3B
$495.0M
Q1 25
$1.3B
$500.8M
Q4 24
$1.1B
$377.0M
Q3 24
$591.0M
$376.3M
Q2 24
$668.2M
$376.8M
Q1 24
$750.0M
$349.3M
Debt / Equity
LEU
LEU
TARS
TARS
Q4 25
1.54×
0.21×
Q3 25
3.23×
0.22×
Q2 25
1.09×
0.22×
Q1 25
1.82×
0.21×
Q4 24
2.93×
0.32×
Q3 24
1.09×
0.30×
Q2 24
1.13×
0.28×
Q1 24
2.56×
0.11×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LEU
LEU
TARS
TARS
Operating Cash FlowLast quarter
$-48.4M
$19.3M
Free Cash FlowOCF − Capex
$-58.0M
$13.0M
FCF MarginFCF / Revenue
-39.7%
8.6%
Capex IntensityCapex / Revenue
6.6%
4.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$31.3M
$-22.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LEU
LEU
TARS
TARS
Q4 25
$-48.4M
$19.3M
Q3 25
$10.1M
$18.3M
Q2 25
$52.8M
$-29.4M
Q1 25
$36.5M
$-20.7M
Q4 24
$57.9M
$-22.2M
Q3 24
$-33.2M
$-8.7M
Q2 24
$7.0M
$-14.4M
Q1 24
$5.3M
$-37.8M
Free Cash Flow
LEU
LEU
TARS
TARS
Q4 25
$-58.0M
$13.0M
Q3 25
$5.7M
$16.3M
Q2 25
$49.2M
$-30.4M
Q1 25
$34.4M
$-21.2M
Q4 24
$57.2M
$-22.3M
Q3 24
$-34.2M
$-8.9M
Q2 24
$6.1M
$-15.4M
Q1 24
$3.8M
$-38.0M
FCF Margin
LEU
LEU
TARS
TARS
Q4 25
-39.7%
8.6%
Q3 25
7.6%
13.8%
Q2 25
31.8%
-29.6%
Q1 25
47.1%
-27.1%
Q4 24
37.7%
-33.5%
Q3 24
-59.3%
-18.6%
Q2 24
3.2%
-37.8%
Q1 24
8.7%
-137.5%
Capex Intensity
LEU
LEU
TARS
TARS
Q4 25
6.6%
4.2%
Q3 25
5.9%
1.6%
Q2 25
2.3%
1.0%
Q1 25
2.9%
0.8%
Q4 24
0.5%
0.1%
Q3 24
1.7%
0.6%
Q2 24
0.5%
2.5%
Q1 24
3.4%
0.6%
Cash Conversion
LEU
LEU
TARS
TARS
Q4 25
Q3 25
2.59×
Q2 25
1.83×
Q1 25
1.34×
Q4 24
Q3 24
Q2 24
0.23×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LEU
LEU

Separative Work Units$111.0M76%
Services$21.8M15%
Other$13.4M9%

TARS
TARS

Segment breakdown not available.

Related Comparisons